BCL2 and Merkel cell skin cancer: The synergy between DNA damage and BCL-2 inhibition in MCPyV-positive cell lines provides an explanation for why downregulation of BCL-2 mRNA alone was insufficient to impede tumor growth in patients with metastatic or regionally recurrent MCC [33].